Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Autophagy is central to the maintenance of organismal homeostasis in both physiological
and pathological situations. Accordingly, alterations in autophagy have been linked to …

Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-
acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma …

Germline aberrations in critical DNA-repair and DNA damage–response (DDR) genes
cause cancer predisposition, whereas various tumors harbor somatic mutations causing …

Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs
used daily in oncology include clinical TNM stage, objective response and left ventricular …

PURPOSE Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality
(eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) …

In order to maintain genomic stability, cells have developed sophisticated signalling
pathways to enable DNA damage or DNA replication stress to be resolved. Key mediators of …

Excessive abnormal angiogenesis plays a pivotal role in tumor progression and is a
hallmark of solid tumors. This process is driven by an imbalance between pro-and anti …

The efficacy of therapeutics is dependent on a drug binding to its cognate target.
Optimization of target engagement by drugs in cells is often challenging, because drug …